Table 3.
Comparison of variables in patients with and without PHLF
| Overall, n = 62 | No PHLF, n = 46 | PHLF, n = 16 | p value | |
|---|---|---|---|---|
| Established clinical variables | ||||
| PDR, % | 24.2 (18.0–27.7) | 25.0 (18.0–30.3) | 21.2 (17.8–24.7) | 0.082 |
| R15, % | 4.0 (1.58–6.25) | 2.75 (1.0–6.0) | 4.25 (3.55–7.0) | 0.075 |
| Established MDCT variables | ||||
| FLR, ml | 686.03 (497.67–931.02) | 746.5 (563.7–986.0) | 466.5 (403.4–736.0) | 0.005 |
| Proportion of FLR, % | 41.5 (34.55–60.87) | 49.3 (36.2–64.8) | 33.9 (28.4–37.4) | < 0.001 |
| Weight-adapted FLR, ml/kg | 8.47 (6.73–12.89) | 10.16 (7.45–13.93) | 6.62 (5.31–8.0) | < 0.001 |
| Established gadoxetic acid enhanced variable | ||||
| remnantRLE | 1.21 (0.93–1.54) | 1.35 (1.04–1.66) | 0.91 (0.81–1.09) | 0.001 |
| Functional volume | ||||
| functFLR, ml/kg | 10.92 (7.26–17.59) | 12.93 (8.69–22.2) | 6.44 (4.65–7.57) | < 0.001 |
Data are presented as median and interquartile ranges (IQR)
PHLF post-hepatectomy liver failure, PDR plasma disappearance rate, R15 median retention rate at 15 min, MDCT multidetector CT, FLR future liver remnant, remnantRLE mean relative enhancement of the FLR, functFLR functional future liver remnant